Dr. Yuling Li
- President, Zhejiang Innoforce Pharmaceuticals Co., Ltd.
Dr. Yuling Li is the co-founder and President of Innoforce Pharmaceuticals, a company established in 2018 at Hangzhou, China with the focus of building CDMO capabilities for innovative drug development including nucleic acid products (plasmid DNA and RNA), viral vector and cell therapy and monoclonal antibody products. Prior to Innoforce, Dr. Li was the Sr. Vice President of Process Development and Manufacturing of Apollomics (Foster City, CA and Hangzhou), the R&D Fellow/Director in BioPharmaceutical Development at MedImmune/AstraZeneca (Gaithersburg, MD), the Senior Director in BioPharmaceutical Development at Human Genome Sciences Inc. (now part of GSK, Rockville, MD) and an Associate Scientist at Hoffmann-La Roche Inc. in Nutley, New Jersey. In the past 30 years, Dr. Li led CMC activities for 3 BLA submissions and contributed to 9 approved products plus 30+ biopharmaceuticals through various clinical stages of CMC development.
During the course of her career, Dr. Li published 40+ peer-reviewed articles and book chapters and is the inventor for five issued patents. In 2014, Dr. Li received the Rising Star Award from the Healthcare Businesswomen Association. Dr. Li served as the President (2007-2008), Board of Directors, member of the Advisory Board for the Chinese Biopharmaceutical Association-USA (CBA, www.CBA-USA.org), a non-profit professional organization. Dr. Li also co-founded the Alliance of Chinese-American Biotechnology and Pharmaceutical Associations (ALL-CABPA) in 2008. She is a BayHelix member.